Travere Therapeutics

TVTX · NASDAQ

$52.30+$1.81 (+3.58%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $50.49

TVTX analyst rating

BuyConsensus of 10 analysts over the last 12 months. 90% rate it a buy.

Strong buy0
Buy9
Hold1
Underperform0
Sell0

12-month price target · 16 analysts

Average $75.56 (+44.5% upside)

Low: $62.62
Now: $52.30
High: $93.45

Upgrades and downgrades

The latest rating actions, newest first

TVTX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Guggenheim	Sep 24, 2026	Maintains	Buy	$75.00 → $89.00	66%
Wedbush	Sep 22, 2026	Maintains	Outperform	$76.00	40%
HC Wainwright & Co.	Sep 22, 2026	Maintains	Buy	$67.00	40%
Evercore ISI Group	Aug 10, 2026	Maintains	Outperform	$68.00 → $78.00	52%
Canaccord Genuity	Aug 6, 2026	Maintains	Buy	$62.00 → $70.00	44%
Wedbush	Aug 6, 2026	Maintains	Outperform	$61.00 → $75.00	40%
TD Cowen	Aug 5, 2026	Maintains	Buy	$60.00 → $75.00	49%
Citigroup	Aug 5, 2026	Maintains	Buy	$70.00 → $85.00	42%
Evercore ISI Group	Aug 5, 2026	Maintains	Outperform	$60.00 → $68.00	52%
Guggenheim	Aug 5, 2026	Maintains	Buy	$65.00 → $75.00	66%

The case for and against

Updated Oct 14, 2026

Bull case

Travere Therapeutics is supported by a stronger and more durable Filspari franchise, as the USPTO notice of allowance for FSGS methods could extend US coverage into October 2037, matching the IgAN patent granted in August and reducing a major loss-of-exclusivity risk. Commercial momentum also appears solid, with 2Q26 revenue of $141.1M, 2,012 new patient start forms, and physician survey data showing projected FSGS use rising from ~15% to ~30% within six months, while IgAN usage is expected to increase from 16% to 22%. The leadership transition to Bradley Campbell adds rare-disease commercialization experience at a time when the company has room to diversify beyond Filspari, with attention shifting toward pegtibatinase and civorebrutinib as it moves into 2027.

Bear case

Travere Therapeutics is facing a negative fundamental outlook because its development strategy depends on accelerated regulatory pathways that may still require additional data, longer studies, or changing approval standards, all of which increase execution risk. The company also may need to access capital markets to fund its pipeline and commercial efforts, making it vulnerable to financing constraints that could slow or disrupt development and product commercialization. Combined, these factors suggest a business model with meaningful regulatory uncertainty and ongoing funding dependence, which can pressure long-term value creation.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.